Back to Authors

Lacy, Martha Q.

https://orcid.org/0000-0003-1193-1559

Mayo Clinic

Mayo Clinic

Citations 640

Relationship Between Depth of Response and Outcome in Multiple Myeloma
Dingli, David , Pacheco, Jorge M. , Nowakowski, Grzegorz S. , Kumar, Shaji , Dispenzieri, Angela , Hayman, Suzanne R. , Lacy, Martha Q. , Gastineau, Dennis A., Gertz, Morie A. , Dispenzieri, Angela , Dingli, David

Journal of Clinical Oncology | October 30, 2007 | Volume: 25 | Issue: 31 | Pages: 4933-4937

10.1200/jco.2007.11.7879 Get It

Purpose High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS. Patients and Methods All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated. Results We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55% for BCR and 63% for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39). Conclusion The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Rajkumar, S. Vincent , Richardson, Paul G. , Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Schlossman, Robert, Sidor, Carolyn, Richardson, Paul Gerard Guy , Witzig, Thomas E. , Anderson, Kenneth C. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Clinical Cancer Research | October 18, 2007 | Volume: 13 | Issue: 20 | Pages: 6162-6167

10.1158/1078-0432.ccr-07-0807 Get It

Abstract Purpose: 2-Methoxyestradiol (2ME2) is an endogenous product of estradiol metabolism with antiangiogenic and antineoplastic properties. We report on the first phase II trial of 2ME2 in multiple myeloma. Experimental Design: 2ME2 was administered orally at a dose of 1,000 mg daily. Sixty patients (31 men and 29 women) were treated. After 39 patients were accrued, the dose was increased to 800 mg twice daily for the remaining patients. Results: Thirty-one patients had relapsed or refractory multiple myeloma, and 29 had plateau phase multiple myeloma. Median age was 60 years (range, 27-84 years). Therapy was well tolerated. Common adverse events included anemia (35%), fatigue (35%), nausea (25%), diarrhea (20%), hot flushes (20%), headache (17%), muscle cramps (15%), and upper respiratory tract infection (15%). Most adverse events were mild (grade 1-2); 12% experienced grade 3-4 adverse events. Median time to progression was 3.8 months, with 5.6 months for plateau phase disease and 2.3 months for relapsed multiple myeloma. Estimated progression-free survival rates for all patients at 1, 2, and 3 years were 24%, 17%, and 11%, respectively. Three patients, all with plateau phase disease, have been on study for over 4 years without progression at 50, 60, and 63 months, respectively. Minor response was noted in 2 patients. Conclusions: Although no partial responses have been seen thus far, the minor responses and prolonged stable disease seen with 2ME2 therapy are promising. Plasma levels indicate that the dose of 2ME2 was inadequate. A new formulation with better bioavailability will be tested soon in multiple myeloma.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Richardson, Paul G. , Sonneveld, Pieter , Irwin, David, Stadtmauer, Edward A. , Harousseau, Jean‐Luc, Ben‐Yehuda, Dina, Goldschmidt, Hartmut , Reece, Donna , Bladé, Joan , Boccadoro, Mario , Cavenagh, Jamie, Alsina, Melissa , Rajkumar, S. Vincent , Lacy, Martha Q. , Dalton, William S. , Boral, Anthony, Esseltine, Dixie‐Lee, Schenkein, David P., Richardson, Paul Gerard Guy , Schuster, Michael K. , Facon, Thierry T.F. , Lonial, Sagar , Miguel, Jesús F. San , Jakubowiak, Andrzej , Anderson, Kenneth C. , Rajkumar, S Vincent

Blood | August 9, 2007 | Volume: 110 | Issue: 10 | Pages: 3557-3560

10.1182/blood-2006-08-036947 Get It

Abstract Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).
Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
Kumar, Shaji , VanWier, Scott, Ahmann, Greg, Price-Troska, Tammy, Henderson, Kim, Chung, Tae‐Hoon , Kim, Seungchan , Bryant, Barbara M. , Carpten, John D. , Rajkumar, S. Vincent , Lacy, Martha Q. , Dispenzieri, Angela , Kyle, Robert A. , Greipp, Philip R., Bergsagel, P. Leif , Fonseca, Rafaël , Bergsagel, P. Leif , Chng, Wee Joo , Henderson, Kimberly J., Mulligan, George , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Chung, Tae-Hoon , Fonseca, Rafael

Cancer Research | April 4, 2007 | Volume: 67 | Issue: 7 | Pages: 2982-2989

10.1158/0008-5472.can-06-4046 Get It

Abstract Hyperdiploid multiple myeloma (H-MM) is the most common form of myeloma. In this gene expression profiling study, we show that H-MM is defined by a protein biosynthesis signature that is primarily driven by a gene dosage mechanism as a result of trisomic chromosomes. Within H-MM, four independently validated patient clusters overexpressing nonoverlapping sets of genes that form cognate pathways/networks that have potential biological importance in multiple myeloma were identified. One prominent cluster, cluster 1, is characterized by high expression of cancer testis antigen and proliferation-associated genes. Tumors from these patients were more proliferative than tumors in other clusters (median plasma cell labeling index, 3.8; P < 0.05). Another cluster, cluster 3, is characterized by genes involved in tumor necrosis factor/nuclear factor-κB signaling and antiapoptosis. These patients have better response to bortezomib as compared with patients within other clusters (70% versus 29%; P = 0.02). Furthermore, for a group of patients generally thought to have better prognosis, a cluster of patients with short survival (cluster 1; median survival, 27 months) could be identified. This analysis illustrates the heterogeneity within H-MM and the importance of defining specific cytogenetic prognostic factors. Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients. [Cancer Res 2007;67(7):2982–9]
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Dispenzieri, Angela , Lacy, Martha Q. , Zeldenrust, Steven R., Hayman, Suzanne R. , Kumar, Shaji , Geyer, Susan M. , Lust, John A., Allred, Jacob B., Rajkumar, S. Vincent , Greipp, Philip R., Kabat, Brian, Witzig, Thomas E. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Blood | September 29, 2006 | Volume: 109 | Issue: 2 | Pages: 465-470

10.1182/blood-2006-07-032987 Get It

AbstractPrimary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64%), renal (73%), hepatic (23%), and nerve (14%). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45%), thrombocytopenia (27%), rash (18%), and fatigue (18%). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications
González-Paz, Natalia, McClure, Rebecca F., Blood, Emily, Oken, Martin M., Ness, Brian Van, James, C. David , Kurtin, Paul J. , Henderson, Kimberly J., Ahmann, Gregory , Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Fonseca, Rafaël , Chng, Wee Joo , Gertz, Morie A. , Dispenzieri, Angela , Fonseca, Rafael

Blood | July 14, 2006 | Volume: 109 | Issue: 3 | Pages: 1228-1232

10.1182/blood-2006-05-024661 Get It

Abstract The biological and clinical implications of p16 gene methylation in multiple myeloma (MM) are still unclear despite previous studies. In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n = 17), smoldering multiple myeloma (SMM; n = 40), and MM (n = 522) at a prevalence of 24%, 28%, and 34%, respectively. However, p16 methylation does not appear to affect gene expression level. In a large cohort of patients with long-term follow-up information (n = 439), there was no difference in overall survival between patients with or without p16 methylation. We also found no association between p16 methylation and the main cytogenetic categories, although it was more common among patients with 17p13.1 deletions (p53 locus), a genetic progression event in MM. In addition, p16 methylation has no apparent effect on the cycle because there was also no difference in the plasma cell labeling index (a direct measurement of proliferation) between patients with and without p16 methylation. Our results question a major role for p16 methylation in the oncogenesis of the PC neoplasm, and we now believe p16 methylation may be a marker for overall epigenetic changes associated with disease progression, with no obvious direct biological or clinical consequences.
Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Schop, Roelandt F.J., Price-Troska, Tammy, Jelinek, Diane F., Dispenzieri, Angela , Lacy, Martha Q. , Kyle, Robert A. , Greipp, Philip R., Tschumper, Renee C. , Fonseca, Rafaël , Bergsagel, P. Leif , Chng, Wee Joo , Ghobrial, Irene M. , Kay, Neil E. , Gertz, Morie A. , Bergsagel, P. Leif , Dispenzieri, Angela , Fonseca, Rafael

Blood | June 28, 2006 | Volume: 108 | Issue: 8 | Pages: 2755-2763

10.1182/blood-2006-02-005488 Get It

AbstractWaldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.
Identification of Two Groups of Smoldering Multiple Myeloma Patients Who Are Either High or Low Producers of Interleukin-1
Xiong, Yuning, Donovan, Kathleen A., Kline, Michael, Gornet, Michael K., Moon‐Tasson, Laurie L., Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Lust, John A., Gertz, Morie A. , Dispenzieri, Angela

Journal of Interferon & Cytokine Research | February 17, 2006 | Volume: 26 | Issue: 2 | Pages: 83-95

10.1089/jir.2006.26.83 Get It

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Dispenzieri, Angela , Lacy, Martha Q. , Katzmann, Jerry A., Rajkumar, S. Vincent , Abraham, Roshini S. , Hayman, Suzanne R. , Kumar, Shaji , Clark, Raynell, Kyle, Robert A. , Litzow, Mark R. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana M., Porrata, Luis F. , Elliott, Michelle A. , Johnston, Patrick B. , Greipp, Philip R., Zeldenrust, Steven R., Gastineau, Dennis A., Witzig, Thomas E. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Blood | January 6, 2006 | Volume: 107 | Issue: 8 | Pages: 3378-3383

10.1182/blood-2005-07-2922 Get It

AbstractThe immunoglobulin free light chain (FLC) is the precursor protein of amyloid in primary systemic amyloidosis (AL). Historically, the ability to monitor the amyloid protein precursor protein has been crude. We evaluated the utility of the FLC assay in a retrospective analysis of patients with AL undergoing peripheral blood stem cell transplantation (PBSCT). Ninety-three such patients had serial FLC measurements performed. The prognostic effects of the initial concentration and the extent of reduction of monoclonal FLC on survival were studied. There was a significantly higher risk of death in patients with higher baseline FLC (hazard ratio 2.6, P < .04). Baseline FLC correlated with serum cardiac troponin levels, and higher FLC levels were associated with more organs involved by amyloid, suggesting that high FLC levels may be associated with more advanced disease. The percent FLC reduction did not predict for survival, but the absolute level of FLC achieved after therapy did. Normalization of FLC level after PBSCT predicted for both organ response and complete hematologic response. Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome.
Clinical implication of centrosome amplification in plasma cell neoplasm
Ahmann, Greg, Henderson, Kim, Santana-Dávila, Rafael , Greipp, Philip R., Lacy, Martha Q. , Dispenzieri, Angela , Kumar, Shaji , Rajkumar, S. Vincent , Lust, John A., Kyle, Robert A. , Zeldenrust, Steven R., Hayman, Suzanne R. , Fonseca, Rafaël , Chng, Wee Joo , Henderson, Kimberly J., Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Blood | December 23, 2005 | Volume: 107 | Issue: 9 | Pages: 3669-3675

10.1182/blood-2005-09-3810 Get It

The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability in a variety of tumors and is a potential mechanism causing aneuploidy in MM. Using immunofluorescent (IF) staining, centrosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS). We also investigated the gene expression of centrosome proteins. Overall, gene expression data correlated well with IF-detected centrosome amplification, allowing us to derive a gene expression-based centrosome index (CI) as a surrogate for centrosome amplification. Clinically, MM patients with high CI (> 4) are associated with poor prognostic genetic and clinical subtypes (chromosome 13 deletion, t(4; 14), t(14;16), and PCLI > 1%, P < .05) and are shown here to have short survival (11.1 months versus 39.1 months, P < .001). On multivariate regression, a high CI is an independent prognostic factor. Given that centrosome amplification is already observed in MGUS and probably integral to early chromosomal instability and myeloma genesis, and patients with more extensive centrosome amplification have shorter survival, the mechanisms leading to centrosome amplification should be investigated because these may offer new avenues for therapeutic intervention.